Peptides
Thymosin alpha-1 (TA-1): immune research and the large negative trial
How does it work?
Thymosin alpha-1 is a thymus-derived peptide studied for effects on immune-cell responses. “Immune modulation” can mean different effects in different diseases and does not imply that more immune activity is always desirable. [1]
What do trials show?
Earlier disease-specific studies generated interest, but the large 2025 TESTS phase 3 trial offers an important check. It randomized 1,106 adults with sepsis to thymosin alpha-1 or placebo alongside standard care. In the analyzed population, 28-day deaths were 23.4% versus 24.1%, without a significant difference. That result neither proves failure in every other disease nor supports routine “immune boosting” in healthy adults. [1]
Safety
The trial’s monitored hospital use does not establish safety of self-administered research vials. People with autoimmune disease, transplants, cancer treatment, or immunosuppressive medicines need condition-specific clinical advice rather than generic immune claims.
STUDIED AMOUNT
How much?
SOURCE CONTEXT
What it refers to
subcutaneously every 12 hours for seven days in hospitalized sepsis patients.
The TESTS trial administered 1.6 mg subcutaneously every 12 hours for seven days in hospitalized sepsis patients. This is a studied disease-specific regimen that did not improve the main outcome; it is not a recommended fitness, prevention, or wellness dose. No safe/effective routine immune-support dose of the catalog product is established. [1]
Sources & further reading
- TESTS multicenter randomized sepsis trial, BMJ 2025 (opens in a new tab)pmc.ncbi.nlm.nih.gov